Testing two new medications together for advanced lung cancer

Plain-English translation of NCT07227025 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Read our Carcinoma, Non-Small-Cell Lung research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing a combination of two medications called and in people with advanced lung cancer that has spread to other parts of the body. The cancer being studied has a specific genetic change (called KRAS G12C mutation) that these medications are designed to target. Researchers want to find the right dose of these two medications together and see how well they work to slow or stop cancer growth.

Many people with this type of advanced lung cancer run out of treatment options after standard chemotherapy and immunotherapy stop working. This trial explores whether this new medication combination might help patients whose cancers have progressed despite other treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced lung cancer that has spread to other parts of your body and has the KRAS G12C genetic mutation
your cancer has grown or gotten worse after treatment with chemotherapy combined with or followed by immunotherapy
you have at least one tumor that can be measured on imaging and hasn't been previously treated with radiation
you are in generally good health with an ability to perform normal daily activities (as measured by a standard health assessment)
if you have brain tumors, they must have been previously treated and you must be stable for at least 2 weeks before joining

You likely don't qualify if…

you have a history of a lung condition called interstitial lung disease or pneumonitis
your cancer has other genetic mutations besides KRAS G12C, such as EGFR, ALK, or other specific driver mutations
you have received any prior KRAS inhibitor medications
you have untreated or poorly controlled medical conditions
you have a known allergy or severe reaction to either of the study medications

What participation looks like

In Phase 1, participants receive both medications together while doctors monitor how well they work and watch for any side effects to determine the best dose. In Phase 2, new participants receive this same combination dose. You will continue treatment until your cancer progresses, you experience severe side effects, or another reason to stop is identified. If eligible, you may be able to continue receiving the medications in a long-term extension phase after the main study ends.

AI-generated summary from trial data · Aug 8, 2026 · Not medical advice

Testing two new medications together for advanced lung cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations